Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
41
CYTK Quote, Financials, Valuation and Earnings
Last price:
$66.55
Seasonality move
:
9.68%
Day range:
$63.50 - $67.26
52-week range:
$29.31 - $69.33
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
88.23x
P/B ratio:
61.87x
Volume:
2.2M
Avg. volume:
1.8M
1-year change:
31.92%
Market cap:
$7.9B
Revenue:
$18.5M
EPS (TTM):
-$6.31
Analysts' Opinion
-
Consensus RatingCytokinetics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 9 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $79.56, Cytokinetics, Inc. has an estimated upside of 23.04% from its current price of $66.54.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $55.00 representing 14.94% downside risk from its current price of $66.54.
Fair Value
-
According to the consensus of 13 analysts, Cytokinetics, Inc. has 23.04% upside to fair value with a price target of $79.56 per share.
CYTK vs. S&P 500
-
Over the past 5 trading days, Cytokinetics, Inc. has underperformed the S&P 500 by -4.29% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Cytokinetics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Cytokinetics, Inc. has grown year-over-year revenues for 5 quarters straight. In the most recent quarter Cytokinetics, Inc. reported revenues of $1.9M.
Earnings Growth
-
Cytokinetics, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Cytokinetics, Inc. reported earnings per share of -$2.55.
Enterprise value:
8.1B
EV / Invested capital:
12.04x
Price / LTM sales:
88.23x
EV / EBIT:
--
EV / Revenue:
93.30x
PEG ratio (5yr expected):
-0.60x
EV / Free cash flow:
-17.95x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$77.6M
Return On Assets:
-55.59%
Net Income Margin (TTM):
-862.21%
Return On Equity:
--
Return On Invested Capital:
-120.55%
Operating Margin:
-8613.38%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $7.8M | $3.2M | $87.2M | $463K | $1.9M | |
| Gross Profit | -$2.4M | -$10.3M | $77.6M | -$1.9M | -$743K | |
| Operating Income | -$495.8M | -$524.6M | -$572.9M | -$140.8M | -$166.8M | |
| EBITDA | -$485.6M | -$511.1M | -$563.3M | -$138.4M | -$164.1M | |
| Diluted EPS | -$5.52 | -$5.39 | -$6.31 | -$1.36 | -$2.55 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $494.9M | $884.3M | $561.4M | $1B | $977.3M | |
| Total Assets | $827.5M | $1.1B | $740.6M | $1.4B | $1.4B | |
| Current Liabilities | $80.9M | $76.5M | $77.7M | $109.8M | $142.1M | |
| Total Liabilities | $578.5M | $1.1B | $1.2B | $1.4B | $2B | |
| Total Equity | $249M | -$16M | -$438.8M | -$13.9M | -$521.1M | |
| Total Debt | $239.8M | $725.2M | $731.2M | $770.8M | $1.2B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$438.5M | -$404.4M | -$432.9M | -$101.5M | -$107.5M | |
| Cash From Investing | $349.9M | -$745.4M | $198.7M | -$45.1M | -$71M | |
| Cash From Financing | $82.4M | $1.1B | $416.1M | $3.4M | $330.5M | |
| Free Cash Flow | -$443M | -$407.1M | -$453.4M | -$102.2M | -$116.9M | |
CYTK
Sector
Market Cap
$7.9B
$28.4M
Price % of 52-Week High
93.26%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
-1.63%
-1.32%
1-Year Price Total Return
25.53%
-22.19%
Beta (5-Year)
0.584
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$66.48
200-day SMA
Buy
Level
$44.51
Bollinger Bands (100)
Buy
Level
40 - 62.66
Chaikin Money Flow
Buy
Level
14.6M
20-day SMA
Buy
Level
$65.29
Relative Strength Index (RSI14)
Buy
Level
57.49
ADX Line
Buy
Level
22.48
Williams %R
Neutral
Level
-69.1852
50-day SMA
Buy
Level
$61.22
MACD (12, 26)
Buy
Level
1.60
25-day Aroon Oscillator
Buy
Level
60
On Balance Volume
Neutral
Level
22.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.9825)
Sell
CA Score
(Annual)
Level (-6.0031)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (7)
Sell
Ohlson Score
Level (5.0778)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (4)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.
Stock Forecast FAQ
In the current month, CYTK has received 9 Buy ratings 4 Hold ratings, and 0 Sell ratings. The CYTK average analyst price target in the past 3 months is $79.56.
-
Where Will Cytokinetics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Cytokinetics, Inc. share price will rise to $79.56 per share over the next 12 months.
-
What Do Analysts Say About Cytokinetics, Inc.?
Analysts are divided on their view about Cytokinetics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cytokinetics, Inc. is a Sell and believe this share price will drop from its current level to $55.00.
-
What Is Cytokinetics, Inc.'s Price Target?
The price target for Cytokinetics, Inc. over the next 1-year time period is forecast to be $79.56 according to 13 Wall Street analysts, 9 of them rate the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.
-
Is CYTK A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Cytokinetics, Inc. is a Buy. 9 of 13 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CYTK?
You can purchase shares of Cytokinetics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cytokinetics, Inc. shares.
-
What Is The Cytokinetics, Inc. Share Price Today?
Cytokinetics, Inc. was last trading at $66.55 per share. This represents the most recent stock quote for Cytokinetics, Inc.. Yesterday, Cytokinetics, Inc. closed at $66.54 per share.
-
How To Buy Cytokinetics, Inc. Stock Online?
In order to purchase Cytokinetics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get CYTK Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CYTK
Sector
P/E ratio
--
23.66x
PEG ratio
-0.60x
-0.01x
P/B ratio
61.87x
1.84x
Price / LTM sales
88.23x
1.60x
Growth Metrics
CYTK
Sector
Revenue growth
318.14%
4.85%
Earnings growth
-87.06%
11.15%
Revenue (5-year growth)
-7.22%
6.45%
Earnings forecast
-$1.57
-$0.20
Profitability
CYTK
Sector
Profitability FY 2024
$8.9M
$3.6M
Return on invested capital
-120.55%
-30.98%
Return on assets
-55.59%
-27.62%
Return on equity
--
-36.69%
Earnings Date
Last Earnings Date
Nov
5
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Feb
4
Balance Sheet
CYTK
Sector
Total cash
$965.6M
$27.2M
Short term investments
$981.2M
$25.7M
Total assets
$1.4B
$79.9M
Long term debt
$1.2B
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
64
Is AAPL Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 38x
Buy
69
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
47
PSTG alert for Dec 4
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
41
SMX alert for Dec 4
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
43
HY alert for Dec 4
Hyster-Yale, Inc. [HY] is up 1.92% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
